Foxo Technologies Inc.
FOXO Technologies Inc. is a U.S.-based healthcare and life-sciences company built around two operating areas: healthcare services and Labs/Life research and testing activities. Its business combines acquired healthcare operations with epigenetic biomarker research, bioinformatics services, and royalty/commission-based revenue streams tied to longevity and life-insurance-related activities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueHospital, ancillary, and substance use disorder treatment services delivered through acquired operations.
Epigenetic testing, bioinformatics services, royalties, and life-insurance-related commissions.
Customers
The company serves healthcare patients and payers through its acquired healthcare operations, with revenue driven by hospital and ancillary services and substance use disorder treatment. Its Labs and Life activities sell to research organizations and other counterparties that need epigenetic testing, data processing, or access to FOXO-related biomarker IP. The KR8 app initiative also targets consumer health and wellness use cases, although it remains a licensing and development effort rather than a mature revenue engine.
Patients receive hospital and treatment services, while insurers and government programs reimburse a large share of the revenue.
Buy epigenetic testing and bioinformatics services for data analysis and biomarker-related research.
Generate small revenue streams from biomarker-related royalties and life insurance policy commissions.
Potential users of the AI epigenetic app being developed under the KR8 agreement.
Strategy
Management is focused on keeping the business funded while scaling acquired healthcare operations and extracting cash flow from Myrtle and RCHI/SCCH. The company is also pursuing additional financing and strategic acquisitions that can contribute positive cash flow, while developing bioinformatics and epigenetic product offerings that could broaden the revenue base. Liquidity preservation and selective capital deployment are central because the company states it does not have sufficient capital to fund corporate overhead for at least 12 months without additional financing.
The company says current cash is insufficient to fund overhead without new financing.
Myrtle and RCHI/SCCH are expected to produce a small cash flow surplus through 2025.
Bioinformatics services can broaden the company beyond healthcare reimbursement economics.
The KR8 license and epigenetic testing services could create higher-value recurring revenue.
Geography
FOXO’s disclosed operating territory for the KR8 license is limited to the U.S., Canada, and Mexico, indicating a North American focus for that product initiative. The company is U.S.-based and its healthcare revenue is generated domestically, with reimbursement and collection risk tied to U.S. payer dynamics. No country-level revenue split was disclosed in the provided excerpts.
Risks
FOXO faces substantial going-concern and financing risk because management states it cannot fund operations for at least 12 months without additional capital. Its healthcare revenue is highly exposed to payer reimbursement, contractual allowances, and collection performance, while the Labs/Life business remains small and less proven. The company also carries execution risk around acquisitions, integration, and commercialization of new epigenetic products, all while operating in a regulated healthcare environment.
- Insufficient liquidity / going concernImpact: CriticalLikelihood: High
Management says current cash is not enough to fund corporate overhead for 12 months.
Exposure - Dilution and capital structure riskImpact: HighLikelihood: High
Funding may require equity issuance, convertible debt, or non-cash settlements.
Exposure: Existing shareholders
- Acquisition integration riskImpact: HighLikelihood: Medium
Recent acquisitions must be integrated and turned into positive cash flow.
Exposure - Payer reimbursement and collection riskImpact: High
Healthcare revenue is recorded net of contractual allowances and implicit price concessions.
Exposure: Healthcare segment revenue and receivables
Accounting
Judgemental itemsHealthcare revenue is reduced by estimated allowances and concessions, affecting net sales.
Impact: Reported revenue and accounts receivable
Management estimates what it expects to collect from payers and patients.
Impact: Revenue, receivables, and bad debt-related adjustments
Liquidity shortfall may require additional disclosures and affects financial statement assumptions.
Impact: Balance sheet and disclosure risk
Recent acquisitions can create fair value and integration accounting complexity.
Impact: Assets, liabilities, and future impairment risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Foxx Development Holdings Inc.
FOXXW · Computer Communications Equipment
Exicure, Inc
XCUR · Pharmaceutical Preparations
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Maximus, Inc
MMS · Services-Business Services, NEC
MAXIMUS is a U.S.-based government services contractor that designs and operates tech-enabled programs for federal, state, local, and international public agencies.
Phio Pharmaceuticals Corp.
PHIO · Pharmaceutical Preparations
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Last updated: 24/09/2026